Grow Therapy
We're Hiring!
Grow Therapy Company Growth, Stability & Outlook
What People Are Saying About Grow Therapy
-
Investor Backing & Capital Strength: Public reporting indicates a $150M Series D in March 2026 at a roughly $3B valuation with participation from top-tier investors, signaling substantial capital availability to fund expansion. Coverage across multiple industry outlets corroborates strong investor demand for the company’s infrastructure-led approach.
-
Strategic Partnerships: Integrations span 125+ insurers with explicit expansion into employer and health‑system channels (e.g., bridging EAP sessions to ongoing in‑network care and partnerships like Circle Medical), indicating multi‑channel distribution strength. These footholds are presented as key markers of category leadership in enablement-focused behavioral health.
-
Strong Revenue Growth: Reports tied to the 2026 round cite approximately $1B in annual revenue alongside 7 million visits in 2025 and a national provider network, suggesting rapid scaling in monetized utilization. Broad payer coverage and growing enterprise channels reinforce momentum in top‑line expansion.
